Antenatal Corticosteroid Administration for Preterm Birth

Standard Dosing Regimen

• The American College of Obstetricians and Gynecologists recommends administering betamethasone 12 mg intramuscularly in two doses, 24 hours apart, to women with singleton pregnancies between 34 0/7 and 36 6/7 weeks of gestation who are at high risk of delivery within the next 7 days and before 37 weeks 1, 2
• If betamethasone is unavailable, dexamethasone 12 mg intramuscularly in two doses, 24 hours apart, is an acceptable alternative 3

Clinical Benefits

• Antenatal corticosteroids reduce respiratory distress syndrome by 29% (RR 0.71, 95% CI 0.65-0.78) and decrease the need for respiratory support by 20% (RR 0.80, 95% CI 0.66-0.97) in preterm infants 1
• The American College of Obstetricians and Gynecologists found a reduction of 33% (RR 0.67, 95% CI 0.53-0.84) in severe respiratory complications with antenatal corticosteroid use 1, 2

Specific Indications for Administration

• High-risk criteria for antenatal corticosteroid administration include preterm labor with intact membranes and cervical dilation ≥3 cm or ≥75% cervical effacement, as recommended by the American College of Obstetricians and Gynecologists 1, 2, 3

Critical Contraindications

• The American College of Obstetricians and Gynecologists advises against administering antenatal corticosteroids in patients with pregestational diabetes mellitus due to the increased risk of severe neonatal hypoglycemia 1, 2, 4
• Antenatal corticosteroids should not be given to patients with a low likelihood of delivery before 37 weeks, as recommended by the American College of Obstetricians and Gynecologists 1, 2, 5

Special Populations

• The American College of Obstetricians and Gynecologists recommends considering antenatal corticosteroid administration in multiple gestations reduced to singleton on or after 14 0/7 weeks of gestation, with shared decision-making 2
• For twin pregnancies less than 34 weeks, the standard regimen of antenatal corticosteroids should be administered, as recommended by the American College of Obstetricians and Gynecologists 3

Important Clinical Considerations

• The American College of Obstetricians and Gynecologists advises against delaying medically indicated delivery to complete the steroid course in the late preterm period 5
• Thorough counseling is mandatory, as patients must understand that long-term neurodevelopmental risks remain uncertain despite established short-term benefits, as recommended by the American College of Obstetricians and Gynecologists 1, 2, 3

Common Pitfalls to Avoid

• The American College of Obstetricians and Gynecologists warns against overuse in low-risk patients, as this exposes infants to unnecessary risks without benefit 1, 2
• Use in diabetic patients is contraindicated due to the increased risk of severe neonatal hypoglycemia, as recommended by the American College of Obstetricians and Gynecologists 1, 2, 4

Late‑Preterm Antenatal Corticosteroid Guidance (34⁰–36⁶ weeks)

Indications for a Single Course

• In singleton pregnancies between 34⁰ and 36⁶ weeks that meet any high‑risk criteria for delivery within the next 7 days, a single course of betamethasone 12 mg IM (two doses 24 h apart) is recommended (GRADE 1A). High‑risk criteria include:

Evidence from the ALPS Trial

• In the Antenatal Late‑Preterm Steroids (ALPS) trial, only 16.4 % of women who received late‑preterm steroids ultimately delivered at term, highlighting the importance of strict patient selection to preserve benefit. 8
• Clinicians should be equally selective in routine practice to avoid exposing term neonates to unnecessary steroid‑related risks. 8

Absolute Contraindications

• Pregestational diabetes mellitus is an absolute contraindication to antenatal corticosteroids because of a markedly increased risk of severe neonatal hypoglycemia (GRADE 1C). 7
• Women with a low likelihood of delivering before 37 weeks should not receive corticosteroids, as potential harms to the neonate outweigh any benefit (GRADE 1B). 7

Special Populations

• For twin pregnancies in the late‑preterm window (34–36 weeks), shared decision‑making is recommended due to insufficient evidence. 8
• In multiple gestations that have been reduced to a singleton at ≥ 14⁰ weeks, a single course of corticosteroids may be considered (GRADE 2C). 7

Neonatal Hypoglycemia

• Neonatal hypoglycemia occurs more frequently after betamethasone exposure, but 93 % of cases are mild, resolve within < 24 hours, and are self‑limited. 7
• Infants who develop hypoglycemia after maternal steroids have a lower likelihood of prolonged NICU stay (> 3 days). 7

Patient Counseling Requirements

• Comprehensive counseling must be provided regarding the short‑term neonatal benefits and the uncertain long‑term neurodevelopmental risks of antenatal corticosteroids (GRADE 1C). 7
• Ongoing follow‑up of the ALPS cohort includes neurocognitive assessment of offspring at 6 years of age. 8

Antenatal Corticosteroid Use in Preterm Birth Risk (Cited Evidence)

Risks of Repeated Courses

• Repeated antenatal corticosteroid doses are associated with reductions in infant birthweight and head circumference, indicating potential growth‑restriction effects when courses are given more than once. 9, 10

Hypertensive Disorders in Pregnancy

• For women diagnosed with pre‑eclampsia at ≤34 weeks’ gestation, administration of antenatal corticosteroids to promote fetal lung maturity should be considered. 9, 10
• For women with gestational hypertension at ≤34 weeks’ gestation, corticosteroids should be given only when delivery is anticipated within the next 7 days, to balance benefits against possible harms. 9, 10
• A rescue corticosteroid dose may be considered for women ≤34 weeks’ gestation who remain at high risk of preterm delivery ≥ 14 days after an initial course, provided the clinical scenario justifies additional treatment. 9, 10

Elective Cesarean Section

• Antenatal corticosteroids may be considered for women undergoing elective cesarean delivery at ≤38 weeks’ gestation to reduce the incidence of neonatal respiratory morbidity. 9, 10

Antenatal Corticosteroid Recommendations for Fetal Lung Maturity

Standard Agent and Dosing

• The American College of Obstetricians and Gynecologists (ACOG) recommends betamethasone 12 mg intramuscularly, administered as two doses 24 hours apart, for women at risk of preterm delivery. This regimen is applicable to both early‑preterm (≈24–35 weeks) and late‑preterm (≈35–37 weeks) gestations. [11][12]

Indications by Gestational Age

Early‑Preterm (≈24 – 35 weeks)

• Betamethasone should be given to all women who are likely to deliver within 7 days, as the greatest neonatal benefit occurs when birth happens 24 hours to 7 days after the first dose. [11][12]

Late‑Preterm (≈35 – 37 weeks)

• ACOG advises offering betamethasone only to singleton pregnancies with a high risk of delivery within 7 days (e.g., cervical dilation ≥3 cm, membrane rupture, or obstetric indications such as preeclampsia). This recommendation carries a GRADE 1A strength. [11][12]
• In this population, betamethasone reduces the need for any respiratory support by ≈20 % (RR 0.80) and severe respiratory morbidity by ≈33 % (RR 0.67). 11

Contraindications and Cautions

• Pregestational diabetes mellitus is an absolute contraindication because maternal corticosteroid exposure markedly raises the risk of severe neonatal hypoglycemia; recommendation strength GRADE 1C. [11][12]
• Administration is discouraged when there is a low likelihood of delivery before 37 weeks, to avoid unnecessary fetal exposure; recommendation strength GRADE 1B. [11][12]
• Re‑dosing in the late‑preterm period should be avoided, as repeated courses are linked to reduced birthweight and head circumference. (No citation needed for this statement as it lacks a reference.)

Special Populations (Clinical Judgment Required)

• Multiple gestations reduced to a singleton ≥14 weeks – consider a single course of betamethasone; recommendation strength GRADE 2C. [11][12]
• Fetal anomalies or anticipated delivery within <12 hours – consider a single course of betamethasone; recommendation strength GRADE 2C. [11][12]

Patient Counseling

• Clinicians should counsel patients that while short‑term neonatal benefits (e.g., reduced respiratory distress) are well‑established, the long‑term neurodevelopmental impact remains uncertain; recommendation strength GRADE 1C. [11][12]